On May 26, 2026, the Minnesota Governor Tim Walz signed into law the 2026 Omnibus Cannabis Bill. Sponsored by Representative Jessica Hanson (DFL-Burnsville), the law represents a sweeping set of reforms to the state’s regulated cannabis industry, touching everything from medical cannabis access and supply chain logistics to hemp-industry lifelines and a brand-new license category. Representative Hanson described it as a “collaborative effort” involving more than 80 stakeholders and weekly meetings over the course of three months. Here is a breakdown of the law’s most significant provisions and what they mean for Minnesota’s cannabis landscape.
Merging the Medical and Adult-Use Supply Chains
Perhaps the most consequential change in the law is the merger of Minnesota’s currently bifurcated medical and adult-use cannabis supply chains. Under current law, cannabis businesses that participate in both markets must maintain separate cultivation, manufacturing, and inventory tracking systems—including separate instances within the state’s Metrc seed-to-sale tracking platform. The omnibus bill eliminates this dual-track requirement and allows businesses with a medical cannabis endorsement to serve patients and adult-use customers from a single, unified operation.
This change was driven by a legislative mandate from the 2025 session, which directed the Office of Cannabis Management to develop a proposal addressing co-location of cultivation and manufacturing, shared equipment, and continued access for patients with rare and childhood diseases. OCM delivered that proposal on January 15, 2026, following a six-month engagement process with patients, businesses, advocates, and Tribal partners. The supply chain streamlining proposal now forms Article 3 of the omnibus bill.
Strengthening Medical Cannabis Patient Protections
The law does not simply merge the supply chains and call it a day. It builds in a robust set of patient protections to ensure that the medical market does not get lost in the shuffle. Businesses holding a medical retail endorsement must employ a licensed pharmacist or medical cannabis consultant to provide patient consultations. They must establish priority service protocols for patients, such as dedicated service lines, curbside pickup, and advance ordering. They must also carry all products identified by OCM as having high medical need, and other cannabis businesses must be prepared to provide medical products within 24 hours of a patient request.
Representative Hanson highlighted the urgency of this provision, noting that patients—including children—have experienced limited access to medical products at a small number of companies, and that conditions such as epilepsy, cancer, and debilitating autoimmune diseases are at stake. The law also ensures that certain medical cannabis products are not subject to adult-use potency limits and permits hemp-derived cannabinoids in medical products.
The New Macrobusiness License
To replace the existing medical cannabis combination business license, the law creates a new macrobusiness license, effective January 1, 2027. The macrobusiness sits at the top of Minnesota’s size-tiered licensing framework, with an indoor canopy limit of up to 38,000 square feet—significantly reduced from the current 90,000 square feet for medical combination businesses—and up to eight retail locations. Macrobusinesses operating more than five retail locations must ensure that at least three are located in areas identified by OCM as high medical need areas. The law also caps the total number of macrobusiness licenses at eight before January 1, 2030, and requires OCM to convert all existing medical cannabis combination business licenses or applications to macrobusiness licenses or applications by January 1, 2027.
The macrobusiness is the only license type that would be required to serve the medical market, with obligations including holding at least two medical endorsements and maintaining retail locations in high-medical-need areas. Representative Nolan West (R-Blaine), while broadly supportive of the underlying bill, called the canopy reduction “the worst part of the bill,” warning that cutting the canopy from 90,000 to 38,000 square feet mid-stream could invite litigation.
Notably, the final language of the law provides that after its first license renewal, a macrobusiness may receive an additional 2,000 square feet of plant canopy; after the second renewal, another 2,000 square feet; and after the third renewal, an additional 3,000 square feet—provided the business remains in good standing with OCM.
The law also establishes a petition process through which microbusinesses and mezzobusinesses can request reclassification to a higher license tier, with priority given to businesses holding medical endorsements and equal allocation between social equity and non-social equity operators.
Incentives for Medical Endorsement Holders
The law creates meaningful incentives for businesses that voluntarily obtain a medical cannabis endorsement. Cultivators, mezzobusinesses, and microbusinesses that hold a medical cultivation endorsement would receive additional canopy allowances: microbusinesses would gain an additional 1,000 square feet indoors (or one-quarter acre outdoors), mezzobusinesses an additional 3,000 square feet indoors (or one-half acre outdoors), and cultivators an additional 6,000 square feet indoors (or one acre outdoors). Businesses receiving this bonus must sell one-quarter of their additional harvest to other businesses with medical endorsements.
In addition, businesses holding a medical retail endorsement may qualify for additional retail locations—one extra for microbusinesses, up to two for mezzobusinesses, and up to three for cannabis retailers—provided the additional locations are in areas identified by OCM as high medical need areas. All retail businesses with a medical endorsement may deliver products directly to registered patients and designated caregivers—an activity previously restricted to certain license types. Microbusinesses and mezzobusinesses with a medical endorsement also gain the authority to transport products to other cannabis businesses, a capability previously reserved for licensed transporters and the medical combination business.
A Lifeline for the Hemp Industry
With a federal ban on hemp products containing more than 0.4 milligrams of THC per container set to take effect on November 12, 2026, the law provides what Representative Hanson described as “a bridge” for Minnesota’s hemp businesses. The law removes the current prohibition on the same person or entity holding both a hemp business license and a cannabis license, allowing hemp operators to pivot into the regulated cannabis market if the federal ban renders their current product lines unviable.
The law also authorizes the sale of a new “ratio hemp-infused cannabis product” containing no more than 100 milligrams of certain cannabinoids (CBD, CBG, CBN, or CBC) per serving, a maximum of 10 milligrams of THC per serving, and 200 milligrams of THC per package for edibles (or two servings per container for beverages). Representative West praised this provision, saying the law “saves the hemp industry” by creating new products hemp companies can sell.
Streamlined Reporting and OCM Oversight
The law reorganizes and simplifies the study and reporting requirements for the Office of Cannabis Management under Minnesota Statutes § 342.04. Under current law, OCM’s reporting obligations are spread across multiple overlapping provisions. The law consolidates these into a cleaner structure: an annual market analysis on the status of the regulated cannabis industry, and a separate annual report to the legislature each January 15.
Several detailed reporting mandates are removed, including requirements for OCM to recommend funding levels for law enforcement training, drug recognition experts, canine retirement, education programs for youth and pregnant individuals, and county social services. In their place, the law requires the annual report to include updated information on impaired driving data, secondhand smoke effects, mental health and substance use disorder service utilization, and first-episode psychosis programs. The law also adds a new requirement for OCM to collaborate with a broad range of state agencies and organizations on education, prevention, and public safety initiatives.
Psilocybin: A First Step
As a first step toward establishing a psilocybin therapeutic use program in Minnesota, the law requires OCM to publish and submit a report to the Legislature by January 15, 2027, with recommendations on administering a program for individuals 21 and older with a qualifying medical condition. The office is also directed to regularly analyze the availability of federal funding to support the program’s establishment.
Other Notable Provisions
The law includes a number of additional provisions that touch various corners of the industry. Local governments are required to adopt ordinances placing reasonable restrictions on cannabis business operations, and the law clarifies that local governments required to issue one business registration per 12,500 residents should round up to the next whole number.
OCM gained the authority to revoke an applicant’s qualified applicant status if the applicant is ineligible under state law, and may deny final license authorization where a proposed location would violate local zoning ordinances or state fire or building codes. The law also changes the preliminary license approval extension from discretionary to mandatory, requiring OCM to grant an initial six-month extension upon an applicant’s request, with the possibility of an additional six-month extension for applicants who have made good faith efforts. The office is also empowered to inspect unlicensed facilities where lower-potency hemp edibles are manufactured, processed, or sold, and to assess civil penalties against those facilities.
On the social equity front, the law allows a person to hold up to four social equity licenses with up to 33% ownership in each, and OCM is required to formally classify and identify which licenses are designated for social equity applicants. Licensed cannabis and hemp activities in compliance with state law are declared lawful and protected from seizure or prosecution.
Looking Ahead
Unless otherwise specified, most provisions of the law become effective on August 1, 2026, while provisions related to the creation of the macrobusiness license and conversion of existing medical cannabis combination businesses become effective on January 1, 2027. This staggered timeline gives OCM time to build out the endorsement infrastructure and update its tracking systems. In the meantime, cannabis businesses—especially those with medical endorsements or those considering applying for one—should begin evaluating how these changes will affect their operations, compliance obligations, and strategic positioning.
For hemp businesses, the clock is already ticking: the federal THC limit takes effect November 12, 2026, and the dual-licensing pathway created by this law offers a critical strategic option that requires advance planning.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]
